Multithread effectively and personalize outreach to convert deals faster
Elevate social presence and drive business growth from social media
Identify and prioritize high-intent leads, and improve sales effectiveness
Find and connect with ICP attendees, and improve event outcomes
Singulex, Inc. was an immunodiagnostics company that revolutionized biomarker detection with its proprietary Single Molecule Counting (SMC™) technology. This ultrasensitive platform enabled the measurement of proteins and other biomarkers at concentrations far below traditional methods, offering significant potential in early disease detection and management, particularly in cardiovascular, neurological, and oncological fields. Singulex developed and commercialized assays and systems for both research and clinical diagnostic use. In May 2019, Singulex was acquired by PerkinElmer, and its technology and assets became part of PerkinElmer's diagnostics portfolio, which subsequently transitioned to Revvity.
The Alameda headquarters served as the company's primary center for research and development, corporate administration, product manufacturing, and strategic operations for its advanced immunoassay technologies.
The facility likely featured state-of-the-art R&D laboratories, specialized cleanroom environments for assay development and manufacturing, and collaborative office spaces, typical of a cutting-edge biotech company within the Harbor Bay Business Park.
Singulex was known for a scientifically driven, innovative, and mission-oriented work culture. Employees were typically focused on advancing diagnostic capabilities and making a tangible impact on healthcare through technological breakthroughs.
This headquarters was pivotal for the invention, development, and commercialization of Singulex's core SMC™ technology, establishing the company as a leader in the field of ultrasensitive diagnostics and attracting global attention.
Before its acquisition, Singulex was actively expanding its global footprint, primarily focusing on North America and Europe. Its innovative SMC™ technology and diagnostic assays were utilized by pharmaceutical companies, clinical research organizations, and diagnostic laboratories internationally. Globally supported functions included sales and marketing of its proprietary platforms, distribution, technical and application support, and fostering research collaborations to advance diagnostic science.
1701 Harbor Bay Pkwy, Suite 200
Alameda
CA
USA
Address: BioScience Park Leiden (Specific Singulex address within the park, e.g., Mendelweg 32, 2333 CS Leiden, Netherlands - representative)
To establish a direct Singulex presence in Europe, engage with European clinical and research communities, navigate regional regulatory pathways, and drive adoption of its high-sensitivity diagnostic solutions.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, Singulex' leadership includes:
Singulex has been backed by several prominent investors over the years, including:
Singulex was acquired by PerkinElmer in May 2019 and its assets are now part of Revvity. Consequently, Singulex no longer operates as an independent entity, and there have been no executive hires or exits specifically for 'Singulex' in the last 12 months. Key leadership transitions occurred around the time of its acquisition or cessation of specific operations.
Discover the tools Singulex uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Historically, Singulex likely utilized common corporate email patterns. Given the company's acquisition in 2019 and the subsequent integration of its assets, email addresses using the '@singulex.com' domain are no longer active for company operations.
Common historical patterns included [first_initial][last]@singulex.com (e.g., jdoe@singulex.com) or [first].[last]@singulex.com (e.g., jane.doe@singulex.com).
Format
jdoe@singulex.com
Example
0%
Success rate
Business Wire (PerkinElmer Press Release) • May 30, 2019
PerkinElmer, Inc. announced it had acquired Singulex, Inc., including its advanced Single Molecule Counting (SMC™) technology and its CLIA-certified laboratory assets, aiming to strengthen PerkinElmer's position in high-sensitivity immunoassays for life sciences research and diagnostics....more
GenomeWeb • April 26, 2018
Singulex announced its decision to cease operations of its CLIA-certified clinical reference laboratory by June 2018. This strategic shift was intended to allow the company to concentrate its resources on its core SMC™ technology platform and immunoassay business for research and IVD applications....more
PR Newswire (Singulex Press Release) • January 26, 2017
Singulex unveiled its Singulex Clarity™ system, a fully-automated, in vitro diagnostics (IVD) platform. This system utilized Singulex's proprietary Single Molecule Counting technology to deliver high-precision biomarker detection, aiming to empower clinical laboratories with enhanced diagnostic capabilities for complex diseases....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including Singulex, are just a search away.